Revised outcome of Board Meeting held on 24/03/2026 incorporating additional details in compliance with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aptus Pharma Ltd's board, at a meeting on March 24, 2026, approved a bonus share issue in the ratio of 3:2, meaning 3 bonus equity shares of face value ₹10 each for every 2 shares held. This will increase the paid-up share count from 68.6 lakh shares to 1.71 crore shares by capitalising ₹10.29 crore out of the Securities Premium Account. The company has ₹10.68 crore available in securities premium, comfortably covering the bonus requirement as confirmed by statutory auditor ABKB & Co. The board also approved an increase in authorised share capital and a postal ballot notice to seek members' approval, with CDSL appointed as the e-voting agency. Bonus shares are expected to be credited or dispatched on or before May 23, 2026. The record date for eligibility will be announced later.
Positive for existing shareholders who will receive 50% additional shares (3 for every 2 held), backed by adequate reserves. Share price typically adjusts downward on the ex-bonus date, but the overall value of holdings remains unchanged in the short term. The bonus reflects management's confidence in the company's reserves and is a sign of financial health.